Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1995;18(5):356-63.

[Comparative prospective study of effects of Biovisc and Healonid on endothelial cell loss and intraocular pressure in cataract surgery]

[Article in French]
J Colin  1 , G Renard, M Ullern, M Lablache Combier, C Richard, C Trinquand
Affiliations
  • PMID: 7560771
Clinical Trial

[Comparative prospective study of effects of Biovisc and Healonid on endothelial cell loss and intraocular pressure in cataract surgery]

[Article in French]
J Colin et al. J Fr Ophtalmol. 1995.

Abstract

Purpose: The goal of this trial was to evaluate the efficacy (protective action on corneal endothelium and ability to facilitate the procedure) as well as safety (effect on intraocular pressure and inflammation) of Biovisc (new viscoelastic agent made of 1% sodium hyaluronate produced by bacterial fermentation) versus Healonid) postcataract surgery (manual or phacoemulsification).

Methods: 106 patients, 45 males and 61 females (31-94 years) were included in this prospective randomized multicentre trial and followed up for three months. Specular microscopy and intraocular pressure (IOP) measurement were the main evaluation criteria.

Results: At D 90, no significant difference was observed between the two viscoelastic agents on the mean endothelial cell loss (group Viovis: -8.6%; group Healonid: -6%) as well as on IOP (early peaks were transitory and resolutive).

Conclusion: Biovisc and Healonid were similar in terms of efficacy and tolerance.

PubMed Disclaimer

Substances